For instance, the combined treatment of NSCLC with CAR-T cells targeting both MUC1 and PSCA antigens, along with anti-PD-1 antibodies, effectively enhances the killing capacity of CAR-T cells [47]. Here, PDCD1 is linked to non-small cell lung carcinoma.